Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors

BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: Phase I experience

(2017) A. Elfiky et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibition of heat shock protein 90 (Hsp90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas: Clinical results from phase I trial

(2017) A. J. Wagner et al.   JOURNAL OF CLINICAL ONCOLOGY

An investigation into the potential use of serum Hsp70 as a novel tumour biomarker for Hsp90 inhibitors

(2010) Naveen Dakappagari et al.   BIOMARKERS

BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90

(2009) K. Lundgren et al.   MOLECULAR CANCER THERAPEUTICS

Activity of Dasatinib, a Dual SRC/ABL Kinase Inhibitor, and IPI-504, a Heat Shock Protein 90 Inhibitor, against Gastrointestinal Stromal Tumor-Associated PDGFRAD842V Mutation

(2008) B. Dewaele et al.   CLINICAL CANCER RESEARCH

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

The Lessons of GIST--PET and PET/CT: A New Paradigm for Imaging

(2008) A. D. Van den Abbeele   ONCOLOGIST